Background: Nowadays, the peribulbar block is used as a tool in glaucoma surgery. As a side effect, it increases intraocular pressure that raises the need for adjuvant medication to overcome this problem in the diseased eye. Dexmedetomidine has proven to decrease intraocular pressure (IOP) in the non-glaucomatous eye.
Objectives: In a triple-blinded randomized study, dexmedetomidine as an adjuvant to the peribulbar block was used to decrease IOP in the diseased eye.
Methods: We randomized 98 eyes to three groups, including D50 (35 eyes) with dexmedetomidine 50 µg, D25 (33 eyes) with dexmedetomidine 25 µg, or control group (C) (30 eyes) with the plain peribulbar block. The study was randomized triple-blinded, aiming at testing the effect of dexmedetomidine on IOP after block injection.
Results: The pre-injection IOP was 27.71 ± 2.52, 27.25 ± 3.53, and 26.2 ± 3.57 mmHg in groups D50, D25, and C, respectively, then increased to 29.71 ± 1.69, 30.25 ± 2.36 and 29.4 ± 3.756 in groups D50, D25 and C, respectively, with P >0.05. The pressure decreased after the surgery to 10.86 ± 1.478 in group D50, 10.75 ± 1.63 in group D25, and 10.6 ± 1.589 in group C, with no statistical differences (P > 0.05) between the groups.
Conclusions: Dexmedetomidine did not decrease IOP in the glaucomatous eye.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7472791 | PMC |
| http://dx.doi.org/10.5812/aapm.100673 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Treatment of pseudophakic aqueous misdirection syndrome.
Sci Rep
January 2025
Department of Ophthalmology, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse, 3010, Bern, Switzerland.
To describe the management and clinical course of 12 cases of pseudophakic aqueous misdirection syndrome (AMS). Twelve eyes of 12 Patients diagnosed with pseudophakic AMS between 2021 and 2022 were included. Best-corrected visual acuity, refraction, intraocular pressure (IOP), anti-glaucomatous medication, spectral domain ocular coherence tomography (SD-OCT) and postoperative complications were evaluated.
View Article and Find Full Text PDFNew treatments for glaucoma.
Curr Opin Ophthalmol
January 2025
New York Eye Surgery Center, New York City, New York, USA.
Purpose Of Review: This review highlights new Federal Drug Administration (FDA) approved glaucoma treatments to familiarize providers with immediately available options.
Recent Findings: New FDA-approved treatments include the bimatoprost implant, travoprost implant, direct selective laser trabeculoplasty (DSLT), and ocular pressure adjusting pump. The bimatoprost implant is approved for a single administration with effects lasting for about 1 year, as opposed to the nearly 3-year effect for the travoprost implant.
Emerging trends in long-acting sustained drug delivery for glaucoma management.
Drug Deliv Transl Res
January 2025
School of Pharmacy, Medical Biology Centre, Queen's University Belfast, Belfast, UK.
Glaucoma is an optic neuropathy in which progressive degeneration of retinal ganglion cells and the optic nerve leads to irreversible visual loss. Glaucoma is one of the leading causes of blindness. The pathogenesis of glaucoma is determined by different pathogenetic mechanisms, including increased intraocular pressure, mechanical stress, excitotoxicity, resistance to aqueous drainage and oxidative stress.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Federal Center of Brain and Neurotechnologies, FMBA of Russia, Moscow, Russian Federation.
Background: The priority problem of modern healthcare is irreversible dementia due to the steady increase in morbidity. Among irreversible dementias, Alzheimer's disease takes the first place. Most often, only with sufficiently pronounced cognitive disorders, the doctor can diagnose Alzheimer's disease, although it is obvious that the neurodegenerative process begins even before the clinical manifestations of the disease.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Department of Ophthalmology, University of Washington, Seattle, WA, USA.
Background: To describe the settings and compare demographic and baseline clinical factors of the inaugural Eye Adult Changes in Thought (ACT) study participants.
Method: Adult Changes in Thought (ACT) is an ongoing cohort study of older adults (≥ 65 years) randomly recruited from Kaiser Permanente Washington who were cognitively normal at enrollment and followed biennially for the onset of Alzheimer's disease since 1994. Cognitive testing included the Cognitive Abilities Screening Instrument scored using Item Response Theory (CASI-IRT) with other measures of cognition.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!